No Data
No Data
MannKind Reports 30-week Results From Phase 4 INHALE-3 Study - Quick Facts
Express News | MannKind Corp: Look Forward to Discussing More Details of 30-Week Study Results at Conferences in 2025
Express News | MannKind Corp: Announced Top-Level 30-Week Results From Its Phase 4 Inhale-3 Study
MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
More Adults With Type 1 Diabetes Achieved A1C Goal (
10 Health Care Stocks With Whale Alerts In Today's Session
loading...
No Data
No Data